Navigation Links
Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
Date:9/20/2011

pNET patients is significant. This activity, together with mild-side effect profile, makes NKP-1339 a potentially promising new treatment for this disease," said Dr. Daniel Von Hoff.

"It is gratifying to see someone whose tumor has been resistant to other therapies do well with this promising investigational therapy. The patient has received NKP-1339 for more than a year and continues to benefit," added Dr. Howard Burris.

"We are pleased by these interim results demonstrating the single agent anti-tumor activity of NKP-1339 in patients with advanced cancers refractory to standard treatments," said Dr. Angela Ogden, Chief Medical Officer for Niiki Pharma Inc.

"The preliminary results of this ongoing trial, showing the anti-tumor activity and the safety profile of NKP-1339, support our preclinical studies that the drug targets tumors selectively and is active against different tumors. We are delighted to see years of research come to fruition in collaboration with Niiki Pharma's team," said Professor Keppler, University of Vienna, inventor of NKP-1339.

About NKP-1339NKP-1339 is a first-in-class transferrin targeted ruthenium-based anti-cancer compound. Transferrin receptor is significantly over-expressed in many tumor types. The intracellular target pathways of NKP-1339 include down-regulation of GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.  GRP78 is the cause of resistance in many tumor types. In preclinical studies, NKP-1339 has demonstrated activity against multiple tumor types, including those resistant to other anti-cancer agents, including platinum-containing agents, anthracyclines and anti-tubulins.

NKP-1339 was invented by Professor Bernard K. Keppler, currently the Dean of the Faculty of Chemistry at University of Vienna, Austria, and Head of the Research Platform "Translational Cancer Therapy Research", a multi-disciplinary collaboration between University of Vienna and th
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
3. Nations Pharmacists Ready to Administer Seasonal Flu Vaccines
4. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
5. Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc
6. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
7. Genesis Biopharma Adds Cell Therapy Bioprocess Engineering, Clinical Trial Design, Biostatistics, Regulatory Affairs and FDA Compliance Expertise
8. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
9. Pharmasset to Present at Two Upcoming Conferences
10. MDC Partners Launches Integrated Healthcare Marketing Platform With Acquisition of Majority Stake in Concentric Pharma Advertising
11. Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. ... Phase 2 clinical program of NP001 for the treatment ... disease) are being highlighted today in an oral ... Research Group , being held in Bloomington, ... post hoc  analysis, administration of a high dose of ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. 17, 2014 ... a partnership in the fight against sarcoma. Under ... Alliance Suzanne Renee Leider Memorial Assistance Fund. ... to reimburse sarcoma patients for expenses directly related ... specialist. Scientific literature reinforces the importance of this ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
(Date:9/17/2014)... Many countries choose to kill all infected poultry ... number of poultry exceeds 10 billion in China. Epidemic ... huge losses. Therefore, it is quite necessary to immunize ... vaccines have been used for more than 10 years ... use H5N1 avian influenza vaccines voluntarily 10 years ago ...
(Date:9/17/2014)... The Food and Drug Administration (FDA) ... to consider: , 1. The appropriate ... 2. The potential for adverse cardiovascular outcomes ... litigation ongoing, an informally-organized litigation group subcommittee prepared a ... replacement therapy. Among others, ZKB attorney Michelle L. Kranz ...
(Date:9/17/2014)... BOSTON September 17, 2014 Why are Asian ... than Caucasian Americans, and prone to develop the disease ... may lie in the transition from traditional high-fiber, low-fat ... extra risks for those of Asian heritage, says George ... at Joslin Diabetes Center and the senior author of ...
(Date:9/17/2014)... New York, NY (PRWEB) September 17, 2014 ... morcellators ( http://www.drugbot.com/morcellator/ ) in laparoscopic hysterectomies and other ... LLP reports. According to figures posted on Change.org, at ... September 17th. * , According to a recent report ... one year ago by Dr. Hooman Noorchashm, after his ...
(Date:9/17/2014)... 17, 2014 Cadiz Laser Spa ... cosmetic procedures to clients throughout Central Texas. The ... is Collagen Induction Therapy. Using the revolutionary Rejuvapen ... to help clients correct a wide variety of ... month, and Cadiz Laser Spa is currently offering ...
Breaking Medicine News(10 mins):Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2
... Extended One Year -LEXINGTON, Mass., Jan. 26 ... Chain Systems has extended its contract to offer ... This continues a successful history between the two ... contract covers IL,s portfolio of critical care analyzers, ...
... Medimetriks Pharmaceuticals announced today that the ... Company (Nasdaq: PRGO ), a leading manufacturer ... Exclusive Authorized Distributor of generic versions of Medimetriks, branded ... Medimetriks to receive a percentage of Perrigo,s Net Sales ...
... Authentidate Holding Corp. (Nasdaq: ADAT ... Exchange and workflow management services, announced today that ... LLC and Parascript Management, Inc. (collectively "Parascript") that ... Merger it entered into with Authentidate. The merger ...
... company awardIRVINE, Calif., Jan. 26 ChromaDex Corporation, ... reference standards and contract research, announced today that ... and alternative health care magazine, selected the Company ... Award recipients for its achievement in setting stevia ...
... Jan. 26 Trintech Group Plc (Nasdaq: ... governance, transaction risk management, and compliance solutions, today announced ... will meet on January 27 in Mountain View, California ... to share common experiences, discuss the latest market trends ...
... Health System announced,that it has launched the International ... for robotic surgical teams from around the world.,The launch ... annual,meeting in San Francisco. , ... robotic-assisted,surgery since we began our program in 2002," says ...
Cached Medicine News:Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 2Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 3Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 2Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 3Health News:Authentidate Announces Termination of Merger Agreement With Parascript, LLC 2Health News:Authentidate Announces Termination of Merger Agreement With Parascript, LLC 3Health News:ChromaDex Awarded Nutrition Business Journal Scientific Achievement 2Health News:KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times 2Health News:KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times 3Health News:Saint Joseph's Launches International College of Robotic Surgery 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: